What is HC Wainwright’s Estimate for MIRM FY2028 Earnings?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Equities research analysts at HC Wainwright upped their FY2028 EPS estimates for Mirum Pharmaceuticals in a research report issued on Wednesday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $1.37 for the year, up from their previous forecast of $1.35. HC Wainwright currently has a “Buy” rating and a $81.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 17.40%. The business’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.30) earnings per share. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other research firms also recently weighed in on MIRM. TD Cowen upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a report on Thursday, September 25th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday. Citizens Jmp lifted their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. upped their price objective on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $83.50.

Mirum Pharmaceuticals Stock Down 1.2%

Mirum Pharmaceuticals stock opened at $70.09 on Thursday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.97 and a current ratio of 3.13. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of -81.50 and a beta of 0.75. Mirum Pharmaceuticals has a fifty-two week low of $36.88 and a fifty-two week high of $78.54. The stock’s fifty day moving average is $73.22 and its two-hundred day moving average is $58.67.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Mirum Pharmaceuticals by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 2,540,061 shares of the company’s stock worth $114,430,000 after acquiring an additional 115,327 shares during the period. Contravisory Investment Management Inc. acquired a new stake in Mirum Pharmaceuticals during the 2nd quarter valued at $270,000. Woodline Partners LP grew its holdings in Mirum Pharmaceuticals by 40.0% during the 1st quarter. Woodline Partners LP now owns 566,271 shares of the company’s stock valued at $25,511,000 after purchasing an additional 161,867 shares in the last quarter. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Mirum Pharmaceuticals during the second quarter worth about $11,071,000. Finally, Strs Ohio purchased a new stake in shares of Mirum Pharmaceuticals during the first quarter worth about $550,000.

Insider Activity

In other news, CFO Eric Bjerkholt sold 9,578 shares of the firm’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $76.01, for a total value of $728,023.78. Following the transaction, the chief financial officer owned 39,945 shares of the company’s stock, valued at approximately $3,036,219.45. This trade represents a 19.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Peetz sold 40,000 shares of the firm’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $62.00, for a total transaction of $2,480,000.00. Following the completion of the transaction, the chief executive officer directly owned 138,641 shares in the company, valued at approximately $8,595,742. This represents a 22.39% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 66,578 shares of company stock valued at $4,472,824. Company insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.